title: Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy.
abstract: We assessed prophylactic use of bisphosphonate (BP) in Duchenne muscular dystrophy (DMD) patients on glucocorticoid (GC) therapy.
  
  
  
  Fifty-two DMD patients on daily GC were offered BP (oral risedronate). Patients were reviewed for tolerability, side effects, bone pain, and fracture frequency. Bone mineral density (BMD) was determined by annual dual energy X-ray absorptiometry. BP-treated patients were compared with 15 BP-naïve patients (untreated cohort).
  
  
  
  Side effects occurred in 9 patients. Thirty-six patients continued BP therapy for over 12 months (mean, 3.6 years). Five treated patients reported bone pain. Three treated patients suffered a vertebral fracture, significantly less than in the untreated cohort (5/15). Lumbar spine adjusted BMD Z-scores remained unchanged in treated patients and were significantly greater than in the untreated cohort.
  
  
  
  Prophylactic oral risedronate therapy was tolerated by most DMD patients. It appears to maintain BMD and may reduce fracture rate in DMD patients on GC. Muscle Nerve 54: 79-85, 2016.
authors.affiliation: Department of Pediatric Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
authors.forename: Ramesh
authors.initials: R
authors.lastname: Srinivasan
authors.affiliation: Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
authors.forename: David
authors.initials: D
authors.lastname: Rawlings
authors.affiliation: Department of Pediatric Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
authors.forename: Claire L
authors.initials: CL
authors.lastname: Wood
authors.affiliation: Department of Pediatric Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
authors.forename: Tim
authors.initials: T
authors.lastname: Cheetham
authors.affiliation: The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
authors.forename: Aura Cecilia Jimenez
authors.initials: AC
authors.lastname: Moreno
authors.affiliation: The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
authors.forename: Anna
authors.initials: A
authors.lastname: Mayhew
authors.affiliation: The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
authors.forename: Michelle
authors.initials: M
authors.lastname: Eagle
authors.affiliation: The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
authors.forename: Michela
authors.initials: M
authors.lastname: Guglieri
authors.affiliation: The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
authors.forename: Volker
authors.initials: V
authors.lastname: Straub
authors.affiliation: Department of Pediatric Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.
authors.forename: Catherine
authors.initials: C
authors.lastname: Owen
authors.affiliation: The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
authors.forename: Kate
authors.initials: K
authors.lastname: Bushby
authors.affiliation: The John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom.
authors.forename: Anna
authors.initials: A
authors.lastname: Sarkozy
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D002648:Child; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000517:prevention & control*; D000068296:Risedronic Acid / Q000008:administration & dosage*
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid
keywords: Duchenne muscular dystrophy; bisphosphonate; bone; glucocorticoid; osteoporosis; prophylactic therapy; risedronate